Vaxcyte (NASDAQ:PCVX) Announces Quarterly Earnings Results, Beats Expectations By $0.09 EPS

Vaxcyte (NASDAQ:PCVX) announced its quarterly earnings results on Wednesday. The company reported ($1.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.06) by $0.09, FiscalAI reports. During the same period in the prior year, the company posted ($1.22) EPS.

Vaxcyte Price Performance

Shares of NASDAQ PCVX traded up $1.23 during trading on Wednesday, reaching $55.92. 886,273 shares of the stock traded hands, compared to its average volume of 972,456. Vaxcyte has a 52-week low of $29.08 and a 52-week high of $65.00. The company has a 50-day moving average of $53.56 and a 200-day moving average of $55.10. The stock has a market capitalization of $8.07 billion, a P/E ratio of -8.13 and a beta of 1.23.

Analyst Ratings Changes

PCVX has been the topic of several recent analyst reports. Wall Street Zen cut Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Zacks Research lowered shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vaxcyte in a report on Monday, July 6th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Vaxcyte presently has a consensus rating of “Hold” and an average price target of $86.00.

More Vaxcyte News

Here are the key news stories impacting Vaxcyte this week:

• Positive Sentiment: Quarterly loss was narrower than expected: Vaxcyte reported second-quarter EPS of negative $1.97, beating the consensus estimate of negative $2.06. Although the loss widened from negative $1.22 a year earlier, the earnings beat likely helped sentiment. Vaxcyte quarterly earnings release
• Positive Sentiment: Important VAX-31 trial updates are approaching: Topline safety, tolerability and immunogenicity data from the adult Phase 3 OPUS-1 trial are expected in the fourth quarter of 2026. Results from the OPUS-2 and OPUS-3 trials are expected in the first half of 2027, giving investors several potential catalysts. Vaxcyte second-quarter 2026 business update
• Positive Sentiment: Strong liquidity reduces near-term financing risk: Vaxcyte had approximately $2.5 billion in cash, cash equivalents and investments as of June 30, 2026, providing substantial funding for its late-stage vaccine programs and development of VAX-A1.
• Neutral Sentiment: Analyst consensus remains cautious: Brokerages recently assigned Vaxcyte a consensus “Hold” rating, suggesting that valuation, clinical execution and the company’s ongoing losses remain areas of investor concern. Vaxcyte consensus rating report
• Negative Sentiment: Several executives sold shares: The CFO, COO and another insider sold a combined 29,250 shares for approximately $1.6 million. Each transaction was conducted under a pre-arranged Rule 10b5-1 plan, which reduces the significance of the sales but may still weigh modestly on sentiment.

Insider Transactions at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 2,000 shares of the stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $55.65, for a total transaction of $111,300.00. Following the completion of the transaction, the chief executive officer owned 133,215 shares in the company, valued at $7,413,414.75. This trade represents a 1.48% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Guggenhime sold 10,000 shares of Vaxcyte stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $53.89, for a total transaction of $538,900.00. Following the completion of the transaction, the chief financial officer owned 105,176 shares of the company’s stock, valued at $5,667,934.64. The trade was a 8.68% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 120,646 shares of company stock worth $6,570,810. Insiders own 3.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Royal Bank of Canada lifted its position in shares of Vaxcyte by 115.2% during the first quarter. Royal Bank of Canada now owns 29,471 shares of the company’s stock worth $1,113,000 after acquiring an additional 15,774 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Vaxcyte in the first quarter valued at $219,000. Caxton Associates LLP bought a new stake in shares of Vaxcyte during the 1st quarter valued at $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Vaxcyte by 8.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock valued at $19,409,000 after purchasing an additional 41,034 shares during the period. Finally, Cetera Investment Advisers raised its stake in shares of Vaxcyte by 13.8% during the 2nd quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock valued at $250,000 after purchasing an additional 932 shares during the period. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.